GLP-1 receptor agonists reduced body weight by 12.8%, BMI by 4.8, and waist circumference by 9.8 cm in obese patients without diabetes, with tirzepatide outperforming semaglutide.
15x more likely to lose ≥20% body weightGLP-1 RA-treated obese patients without diabetes were 15 times more likely to achieve 20%+ weight loss compared to placebo
What the researchers found
Meta-analysis of 13 RCTs of GLP-1 RAs in obese/overweight patients without diabetes found:
- Body weight reduction: -12.79% (95% CI: -15.12 to -10.46)
- BMI reduction: -4.80 kg/m² (95% CI: -6.24 to -3.36)
- Waist circumference: -9.78 cm (95% CI: -11.47 to -8.09)
- Systolic BP: -6.32 mmHg (95% CI: -7.92 to -4.72)
- Diastolic BP: -1.95 mmHg (95% CI: -3.21 to -0.69)
Weight loss thresholds vs. placebo (risk ratios):
- ≥5% weight loss: RR 2.98
- ≥10% weight loss: RR 5.56
- ≥15% weight loss: RR 9.50
- ≥20% weight loss: RR 15.00
Tirzepatide showed greater reductions than semaglutide across outcomes.
Why it matters
This meta-analysis specifically addresses obese patients without diabetes — the fastest-growing market for GLP-1 drugs. The nearly 13% average weight loss, substantial waist circumference reduction, and blood pressure improvements demonstrate that these peptide drugs provide clinically meaningful benefits well beyond their original diabetes indication.
How the study worked
Systematic review and meta-analysis following PRISMA guidelines. Searched PubMed, Scopus, Web of Science, and Embase for RCTs of GLP-1 RAs in overweight/obese adults without diabetes. Two reviewers extracted data and assessed quality using Cochrane RoB 2. Thirteen trials were included.
What this study cannot tell us
Only 13 trials were included, and trial durations and specific drugs varied. The comparison between tirzepatide and semaglutide was indirect (not head-to-head trials). Long-term weight maintenance after discontinuation was not assessed. Cost-effectiveness and long-term safety were not evaluated. The review did not separate results by specific GLP-1 RA.
How to read the evidence
This is a systematic review and meta-analysis of randomized controlled trials following PRISMA guidelines with Cochrane RoB 2 quality assessment — representing high-quality evidence synthesis. The 13 included trials provide robust pooled estimates.
When this study was published
Published in 2025, this meta-analysis captures the latest RCT evidence for GLP-1 agonists in non-diabetic obesity, including tirzepatide data.
The bigger picture
GLP-1 agonists have rapidly shifted from niche diabetes drugs to mainstream obesity treatments. This meta-analysis quantifies their impact in the non-diabetic obese population and confirms tirzepatide's superiority — data that supports the expanding clinical use and insurance coverage of these peptide medications for weight management.
Questions still open
- Is the weight loss maintained long-term, or does weight regain occur after stopping GLP-1 drugs?
- At what BMI threshold do the benefits of GLP-1 agonists outweigh the costs and side effects?
- Should tirzepatide replace semaglutide as the first-choice GLP-1 RA for obesity?
Common questions
How much weight can I expect to lose on a GLP-1 drug without having diabetes?
Do GLP-1 drugs only help with weight, or do they improve other health measures too?
Read the original research
Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
Cureus, 17(11), e95938
Citation
Mohamed Ali Elbashir, Roaa; Elbashir, Azza; Urimuke Basake, Robert; Zakaria Ahmed Mohieldin, Amna; I A Elhaj, Najla; Ebrahim Mohamed Ebrahim, Fatima; Gase Ahmed, Waad; Abdelrahim Mohamed Mahgoub, Ola. (2025). Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.. Cureus, 17(11), e95938. https://doi.org/10.7759/cureus.95938